2 721
Alembic Pharma has been actively expanding its product portfolio and regulatory approvals, especially in the U.S. market and is well-positioned for multi-dimensional growth.

It operates a vertically integrated pharmaceutical business, allowing control over the entire value chain—from R&D to manufacturing and global marketing.

Key Segments:
Formulations: Branded generics and specialty drugs across therapeutic areas like cardiology, anti-infectives, diabetology, and gynecology.
APIs (Active Pharmaceutical Ingredients): Supplies to both internal and external clients.
Geographies:
India: Strong branded generics presence.
US: Focus on complex generics and injectables.
Ex-US: Rapidly growing markets in Asia, Africa, and Latin America.

Alembic exports to over 100 countries and is expanding its regulatory footprint. Strategic partnerships and contract manufacturing bolster international presence.

Risks & Challenges
Regulatory hurdles especially in the U.S. and EU.
Pricing pressure in generics, particularly in the U.S.
Competition from both Indian and global pharma players.
Raw Material Volatility - API supply chain risks.

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.